Article Sidebar
Published:
Apr 14, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Application of combined erlotinib and bronchoscopic interventional therapy in the treatment of bronchial lung cancer
Abstract
Purpose: To evaluate the efficacy of combined drug therapy and bronchoscopy intervention in the treatment of bronchial lung cancer.
Methods: A total of 80 patients with bronchial lung cancer admitted in The Third People's Hospital of Xindu District, Chengdu, China were enrolled and assigned in control and study groups (n = 40), and received bronchoscopy intervention alone and combined bronchoscopy intervention/erlotinib therapy, respectively, over a period of 4 weeks. Erlotinib therapy was given by oral administration of 150 mg once daily. Efficacy, levels of serum tumor marker, matrix metalloproteinase (MMP) content, and incidence of adverse reactions in the two groups of patients were evaluated.
Results: The overall response rate (ORR) in the study group was significantly higher than that of the control group (27.5 vs 55.0 %, p < 0.05). Carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), and neuron-specific enolase (NSE) decreased significantly after treatment, when compared to the control group (p < 0.05). Furthermore, after treatment, matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) levels in the study group were lower than in the control group (p < 0.05). The incidence of adverse reactions was 12.5 and 17.5 % in the control and study groups, respective (p > 0.05).
Conclusion: The combination of erlotinib therapy and bronchoscopy intervention significantly improves therapeutic efficacy, as well as serum tumor marker and MMP levels in bronchial lung cancer patients. Furthermore, it is safe as it does not significantly increase the risk of adverse reactions. However, further and broader clinical trials are recommended prior to its application in clinical practice.
